Cures Act Passes Overwhelmingly in the House

The Cures Act passed in the House yesterday. Its 392 to 26 vote suggests that your congressional delegation voted for the Act’s investment in NIH’s management of new and important basic life science research by national labs and research universities. Now (as explained yesterday) you can thank them and while doing so, explain how Bayh-Dole’s commercialization of their investment can attract private sector financial support for patented promising results, leveraging Cures Act congressional appropriations up to ten times by through research university and private sector partnership development initiatives at private sector cost and risk. Such Bayh-Dole investments are absolutely dependent on strong reliable patents obtained by research universities. Continue reading Cures Act Passes Overwhelmingly in the House

Bayh-Dole Explained on Capital Hill

Earlier this week those able to attend were treated to an excellent and important presentation on Capitol Hill discussing the Bayh-Dole Act. It was sponsored by Eagle Forum, whose recently deceased founder Phyllis Schlafly, was a tireless conservative defender of intellectual property. Eagle Forum’s Jim Edwards acted as Moderator. The panelist experts were; erstwhile B-D defender Joe Allen, AUTM’s Stephen Susalka and LES’ Brian O’Shaughnessy. The presentation was illuminating and informative. It definitely is worthy of broader circulation, especially to our congressional delegations. Continue reading Bayh-Dole Explained on Capital Hill

Cures Act High Priority in Lame Duck Session

The two-part, four-week lame duck session (LD) is about to begin. Altered by unforeseen election results, pre-election LD plans have necessarily been altered. Traditionally, a Republican occupied White House and a present and future Republican majority in both chambers would signal smooth LD sailing, clearing a path for the next President. This year’s LD session may be different. On the Republican side, fiscal conservatives may clash with advocates for the debt-funding stimulus of infrastructure and tax cuts. Among Democrats, progressives and centrists may clash over “what went wrong“as their progressive and more pragmatic factions fight it out. Continue reading Cures Act High Priority in Lame Duck Session

Replace and Thus Repeal Bayh-Dole Commercialization

Whatever its outcome, this election marks the start of political turmoil for months to come. In the coming “fog of war”, anti-patent activists will seek fresh support for stale schemes to crush Bayh-Dole’ (B-D’s) commercialization cornerstone. Mega-tech muscle will push new versions of HR 9 litigation on Capitol Hill. Continue reading Replace and Thus Repeal Bayh-Dole Commercialization

Urge 21st Century Cures Act Passage This Year

Having accomplished little leading to November’s election it seems something good actually may clear Congress during the coming lame duck session. A research boosting bill with leadership approval, bi-partisan, bi-cameral floor support, and backed by research universities is gaining pre-election traction for passage in the post-election lame duck session. Described (below) in a Morning Consult piece containing informative links to life science community letters urging lame duck passage, the 21st Century Cures Act bolsters life science with sequestration-starved FDA and NIH funding. Continue reading Urge 21st Century Cures Act Passage This Year

A Discussion Well Worth Watching

Recent emotionally-driven but Bayh-Dole destructive proposals for biopharma price control such as “price-based march-in” and the “UN High Level Panel on Medicinal Access “ Report are ably refuted by Joe Allen who  refers us to a recent Intelligence 2 TV Debate during which it was that demonstrated that rational discussion, rather than simply blaming biopharma for increased overall health care cost is likely to lead to more effective cost-containment outcomes. Emotionally targeted intrusions into our Bayh-Dole based life science commercialization process are not only misdirected but can completely undermine our innovation ecosystem, disrupting NIH’s important basic science commercialization mission in the process. As Joe recommends, Blame Big Pharma for Out of Control Health Care Costs  is a debate “well worth watching”  Continue reading A Discussion Well Worth Watching